CD274 and neoplasm: For example, Phase III trial KEYNOTE-042 trial compared the efficacy of immunotherapy (pembrolizumab) over chemotherapy (platinum-based) in 1274 patients with PD-L1 expression of greater than 1% Tumor Percentage Score (TPS).